Inventiva (NASDAQ:IVA) Given New $18.00 Price Target at Truist Financial

Inventiva (NASDAQ:IVA) had its price objective upped by analysts at Truist Financial from $13.00 to $18.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price objective would indicate a potential upside of 409.05% from the stock’s previous close.

Several other research firms have also commented on IVA. Cantor Fitzgerald began coverage on shares of Inventiva in a research report on Friday, July 17th. They set an “overweight” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th. Guggenheim raised their price target on Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, September 15th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Inventiva presently has a consensus rating of “Buy” and a consensus target price of $15.86.

Inventiva Trading Up 2.2%

IVA traded up $0.08 during trading on Friday, reaching $3.54. The company’s stock had a trading volume of 1,547,517 shares, compared to its average volume of 842,853. The firm has a fifty day simple moving average of $4.34 and a two-hundred day simple moving average of $4.67. Inventiva has a 1 year low of $3.11 and a 1 year high of $7.98.

Inventiva (NASDAQ:IVA) last issued its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The business had revenue of $0.75 million during the quarter. Analysts expect that Inventiva will post -0.81 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of IVA. Propel Bio Management LLC purchased a new stake in shares of Inventiva in the 4th quarter valued at about $4,650,000. Seven Fleet Capital Management LP acquired a new position in shares of Inventiva in the 1st quarter valued at $1,111,000. Eventide Asset Management LLC purchased a new stake in shares of Inventiva in the fourth quarter valued at about $1,155,000. NEXTBio Capital Management LP purchased a new position in shares of Inventiva in the 4th quarter valued at approximately $6,039,000. Finally, Engineers Gate Manager LP increased its holdings in shares of Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after purchasing an additional 43,280 shares during the period. 19.06% of the stock is owned by hedge funds and other institutional investors.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.